Cellectis S.A.

Equities

ALCLS

FR0010425595

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:14 2024-05-03 am EDT			5-day change	1st Jan Change
2.76 ^EUR	+6.15%		+17.70%	-0.14%

May. 03	Cellectis CFO Bing Wang Retires, Interim CFO Appointed	MT
May. 02	Cellectis Announces Chief Financial Officer Changes	CI

Cellectis S.A. Appoints Mathieu Simon as Interim Chief Medical Officer

October 04, 2017 at 04:30 pm EDT

Cellectis S.A. appointed Mathieu Simon M.D. as Interim Chief Medical Officer, effective immediately. Dr. Simon is taking over the responsibilities of Loan Hoang-Sayag, Chief Medical Officer, who is leaving Cellectis to pursue other opportunities. Dr. Mathieu Simon has served as Cellectis' Executive Vice-President since 2012 and as Chief Operating Officer since 2013.

Latest news about Cellectis S.A.

Cellectis CFO Bing Wang Retires, Interim CFO Appointed	May. 03	MT
Cellectis Announces Chief Financial Officer Changes	May. 02	CI
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading	May. 02	MT
Cellectis S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
Cellectis S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 29	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	Apr. 26	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 24	MT
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs	Apr. 22	CI
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	Apr. 22	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	Apr. 16	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	Apr. 11	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Apr. 09	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	Apr. 03	MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	Apr. 02	MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	Apr. 01	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	Mar. 26	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	Mar. 12	MT
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading	Mar. 11	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Feb. 28	MT
European Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday Trading	Feb. 26	MT
European Equities Traded in the US as American Depositary Receipts Rise Friday, Set to End Week Up 1.5%	Feb. 23	MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	Feb. 13	MT

Chart Cellectis S.A.

Duration

Period

More charts

Company Profile

Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR-T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR-T cells for the treatment of cancer patients, and a platform for performing therapeutic genetic modifications in hematopoietic stem cells in a various diseases. Capitalizing on its 23 years of expertise in genome engineering, its TALEN® genome editing technology and its pioneering PulseAgile electroporation technology, Cellectis S.A. is developing innovative product candidates using the power of the immune system to treat diseases with unmet medical needs. As part of its commitment to the search for curative cancer therapies, Cellectis S.A. is developing UCART product candidates directed at the unmet medical needs of patients with certain types of cancer, including acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma. HEAL is a new platform focused on hematopoietic stem cells for the treatment of blood disorders, immune deficiencies, and lysosomal storage diseases.

Sector

Biotechnology & Medical Research

Calendar

12:00pm - American Society of Gene & Cell Therapy Meeting - Abstract Number : 721

More about the company

Income Statement Evolution

More financial data

Ratings for Cellectis S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CELLECTIS S.A.	-0.14%	213M
MODERNA, INC.	+25.69%	47.9B
LONZA GROUP AG	+46.90%	41.42B
IQVIA HOLDINGS INC.	-3.46%	40.7B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B
BIO-TECHNE CORPORATION	+0.17%	12.15B
MEDPACE HOLDINGS, INC.	+28.07%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B

Other Biotechnology & Medical Research